Key statistics
As of last trade Arbutus Biopharma Corp (I9DN:DUS) traded at 3.42, -19.14% below its 52-week high of 4.23, set on Sep 11, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 3.42 |
|---|---|
| High | 3.42 |
| Low | 3.42 |
| Bid | 3.43 |
| Offer | 3.57 |
| Previous close | 3.53 |
| Average volume | 222.22 |
|---|---|
| Shares outstanding | 192.32m |
| Free float | 150.39m |
| P/E (TTM) | -- |
| Market cap | 778.91m USD |
| EPS (TTM) | -0.2219 USD |
Data delayed at least 15 minutes, as of Feb 11 2026 07:11 GMT.
More ▼
Announcements
- Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update
- Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025
- Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update
- Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus
- Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update
- Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025
- Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025
- Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
- Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
- Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO
More ▼
